ENDRA LIFE SCIENCES INC (NDRA)
US29273B3024 - Common Stock
NDRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NDRA as it has an excellent financial health rating, but there are worries on the profitability. NDRA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year NDRA has reported negative net income.
NDRA had a negative operating cash flow in the past year.
NDRA had negative earnings in each of the past 5 years.
In the past 5 years NDRA always reported negative operating cash flow.
1.2 Ratios
NDRA has a Return On Assets of -91.59%. This is amonst the worse of the industry: NDRA underperforms 82.35% of its industry peers.
The Return On Equity of NDRA (-106.34%) is worse than 67.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -91.59% | ||
| ROE | -106.34% | ||
| ROIC | N/A |
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NDRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for NDRA has been reduced compared to 1 year ago.
NDRA has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, NDRA has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -14.32, we must say that NDRA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.32, NDRA is doing worse than 82.89% of the companies in the same industry.
There is no outstanding debt for NDRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.32 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NDRA has a Current Ratio of 4.97. This indicates that NDRA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.97, NDRA is doing good in the industry, outperforming 72.73% of the companies in the same industry.
NDRA has a Quick Ratio of 4.97. This indicates that NDRA is financially healthy and has no problem in meeting its short term obligations.
NDRA has a Quick ratio of 4.97. This is in the better half of the industry: NDRA outperforms 77.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.97 |
3. Growth
3.1 Past
The earnings per share for NDRA have decreased strongly by -271.99% in the last year.
EPS 1Y (TTM)-271.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-551.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, NDRA will show a very negative growth in Earnings Per Share. The EPS will decrease by -87.48% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-337.08%
EPS Next 2Y-87.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NDRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NDRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as NDRA's earnings are expected to decrease with -87.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-87.48%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NDRA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ENDRA LIFE SCIENCES INC
NASDAQ:NDRA (11/21/2024, 8:00:01 PM)
After market: 5.02 -0.25 (-4.74%)5.27
+0.2 (+3.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.74M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -91.59% | ||
| ROE | -106.34% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.97 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-271.99%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-337.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y